Related Experiment Video
Updated: Apr 17, 2026

Author Spotlight: Studying the Epithelial Effects of Intestinal Inflammation In Vitro on Established Murine Colonoids
Published on: June 2, 2023
Nicorandil-induced colonic ulceration.
1Department of General Surgery, Stockport NHS Foundation Trust, Stockport, UK.
This case study highlights nicorandil-induced colonic ulceration as a cause of gastrointestinal symptoms in elderly patients. Prompt identification and cessation of nicorandil are crucial for managing these ulcers.
Area of Science:
- Gastroenterology
- Colorectal Surgery
- Pharmacology
Background:
- Elderly patients with cardiovascular comorbidities may present with nonspecific gastrointestinal symptoms.
- Weight loss and altered bowel habits can be indicative of serious underlying pathology.
Observation:
- Biopsies showed chronic inflammation and reactive changes, but findings were suspicious for malignancy.
- A multidisciplinary team recommended a laparoscopic right hemicolectomy, which was converted to open surgery due to complications.
Findings:
- Postoperative histology of the resected bowel confirmed chronic inflammation without malignancy.
- The ulceration was attributed to an 8-year history of nicorandil therapy, suggesting nicorandil-induced colonic ulceration.
Implications:
- This case highlights the potential for nicorandil to cause significant gastrointestinal pathology, mimicking malignancy.
- Clinicians should consider drug-induced colonic ulcers in patients with relevant medication history and suspicious endoscopic findings.
- Further research into the mechanisms and prevalence of nicorandil-induced gastrointestinal complications is warranted.
More Related Videos
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
06:24Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
Published on: October 13, 2023
Related Concept Videos
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...